2025-524131-39-00招募中3 期
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12]
Charite Universitaetsmedizin Berlin KöR17 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2026年8月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 112
- 试验地点
- 17
- 主要终点
- Progression-free survival, defined as the time from the date of randomization to the date of first radiological disease progression according to RECIST 1.1 or the date of death from any cause. Date of the last contact known alive respectively date of the last tumor assessment known progression-free.
研究概览
简要总结
To compare the efficacy of doublet chemotherapy with FOLFOX and triplet chemotherapy with mFOLFIRINOX in first-line treatment of SBA
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Patient’s signed informed consent.
- •Patients without anticoagulation need to present with an INR <1.5x ULN and PTT <1.5x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
- •Proficient fluorouracil metabolism as defined: - Prior treatment with 5-FU or capecitabine without unusal toxicity or - If tested, normal DPD deficiency test according to the standard of the study site or - If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%
- •For women of childbearing potential (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study treatment. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male partner’s sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. For men with female partners of childbearing potential: men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period. Men with pregnant female partners must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo.
- •Patient’s age ≥18 years at the time of signing the informed consent.
- •Histologically confirmed small bowel adenocarcinoma.
- •Microsatellite stable tumor or proficient mismatch repair status of the SBA (immunohistochemistry and polymerase chain reaction are both allowed for characterization)
- •Predicted locally advanced irresectable by the local study team or presenting with distant metastases.
- •Patient did not receive antitumor treatment for locally advanced irresetable or metastatic disease.
- •Measurable lesion according to RECIST 1.
- •ECOG performance status 0-
- •In case of patient’s age >70 years, ECOG has to be 0 or 1 at randomization.
- •Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results: • Absolute neutrophil count ≥ 1.5 x 109/L (1500/µL) • Hemoglobin ≥ 80 g/L (8 g/dL) with or without blood transfusion • Platelet count ≥ 100 x109/L (100000/µL) without transfusion • Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN) • Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) ≤ 2.5 × ULN; if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN • Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL/min or serum creatinine≤ 1.5x ULN
排除标准
- •Adenocarcinoma of the ampulla of Vateri
- •Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.
- •Known hypersensitivity to 5-FU, leucovorin, capecitabine, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding SmPC.
- •Recent or concomitant treatment with brivudine.
- •Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 6.0 (see appendix 2)).
- •Simultaneous application of Johannis herbs preparations.
- •Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization that may interfere with systemic therapy as judged by the investigator
- •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
- •Medical history of malignant disease other than SBA with the following exceptions: 18.1.patients who have been disease-free for at least three years before randomization 18.
- •patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer 18.
- •patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 80% and does not require active therapy at randomization
- •Alcohol abuse, drug dependence, or substance abuse that may interfere with the patient's ability to comply with the requirements of the trial.
- •Ileus or directly imminent ileus as assessed by the local study team. Patients with treated and resolved ileus are allowed into the trial.
- •Pregnant or breastfeeding females
- •Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.
- •Patients dependent on Sponsor, investigator or study site.
- •Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
- •The patient is unable to provide informed consent because they are unable to understand the nature, significance, and implications of the clinical trial and, consequently, are unable to make a rational decision based on the information provided (limited legal capacity).
- •Inability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.
- •Previous chemotherapy for metastatic or irresectable disease.
- •New York Heart Association Class III or greater heart failure by clinical judgement.
- •Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.
- •Unstable angina pectoris.
- •Unstable cardiac arrhythmia >grade 2 NCI CTCAE despite anti-arrhythmic therapy.
- •Ongoing toxicities >grade 2 NCI CTCAE, in particular peripheral neuropathy.
- •Active uncontrolled infection by investigator’s perspective.
结局指标
主要结局
Progression-free survival, defined as the time from the date of randomization to the date of first radiological disease progression according to RECIST 1.1 or the date of death from any cause. Date of the last contact known alive respectively date of the last tumor assessment known progression-free.
Progression-free survival, defined as the time from the date of randomization to the date of first radiological disease progression according to RECIST 1.1 or the date of death from any cause. Date of the last contact known alive respectively date of the last tumor assessment known progression-free.
次要结局
- Overall survival (OS), is defined as the time from the date of randomisation to the date of death (from any cause). The date of the last contact known alive respectively date of the last tumor assessment known progression-free will be censored at the date of last data entry.
- Objective respone rate (ORR), defined as rate of complete (CR) and partial responses (PR) during study treatment compared to baseline according to RECIST 1.1.
- Depth of response (DpR), defined as change in percent from baseline to smallest tumor diameter (measurements according to RECIST 1.1 definition).
- Type, incidence, severity, and causal relationship to study treatment of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 6.0).
- Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L
研究者
Project Coordinator
Scientific
Charite Universitaetsmedizin Berlin KöR
研究点 (17)
Loading locations...
相似试验
招募中
3 期
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old2025-521619-37-00Unicancer160
招募中
3 期
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.2024-511070-68-01Centre Hospitalier Universitaire De Dijon294
尚未招募
4 期
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNCT07446465Ye Xu42
尚未招募
3 期
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal CancerNCT07472868J. W. A. Burger394
撤回
1 期
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic LeukemiaNCT07428486M.D. Anderson Cancer Center24